New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause

Johnson & Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care

Johnson & Johnson (NYSE: JNJ) today released new findings that show most women know menopause can affect mood and sleep, but fewer than half realize their eye health may change too. A new global survey of 6,000 women found that only 40% connect eye changes with the menopause transition—even though 90% say seeing clearly and comfortably helps them feel confident, capable or like themselves. i

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001236330/en/

During Menopause Awareness Month, Johnson & Johnson is continuing its collaboration with Academy Award–nominated actress, entrepreneur and menopause advocate, Naomi Watts.

During Menopause Awareness Month, Johnson & Johnson is continuing its collaboration with Academy Award–nominated actress, entrepreneur and menopause advocate, Naomi Watts.

During Menopause Awareness Month, Johnson & Johnson is continuing its collaboration with Academy Award–nominated actress, entrepreneur and menopause advocate, Naomi Watts. The American Optometric Association (AOA) is supporting the effort to encourage women to recognize eye and vision changes and speak with an eye care professional.

"We're talking more openly about menopause, but eye health is still too often left out," said Naomi Watts, founder of Stripes Beauty. "I want women to know they don't have to quietly work around changes like dry eyes or blurry vision. An eye exam is a simple step that can help them understand their eye health options and feel more in control."

A common—but often overlooked—midlife change

The new survey, conducted across the United States, United Kingdom, Brazil, South Korea, Japan and China, points to a clear awareness gap. While 75% of women have taken action to manage changes associated with midlife, only 18% have booked an annual eye exam as part of that routine.

The survey also found:

  • 66% have experienced dry, gritty or irritated eyes, and 60% have experienced blurred vision.
  • Only 18% have discussed these changes with an eye care professional.
  • Among women who have not sought help for vision changes, 31% have used a phone flashlight to read a menu or relied on other workarounds, such as enlarging text or holding reading material farther away.

"Too many women are simply adapting to midlife vision changes without realizing there are solutions available," said Dr. Charissa Lee, Head of Professional Affairs, Vision, MedTech, Johnson & Johnson. "By making eye health part of the menopause conversation, we can help women find the options that support clear, comfortable vision and everyday confidence."

Midlife vision changes can happen at the same time as the menopause transition and its possible eye health changes. Symptoms may include dry or irritated eyes, blurry near vision, headaches, or needing to hold reading material farther away. ii A comprehensive eye exam can help identify what is changing and which options, like multifocal contact lenses, may better support the patient's lifestyle.

Turning awareness into action

Watts will continue sharing her eye health journey and encouraging women to include vision in their midlife wellness routine. The AOA will encourage women to make comprehensive eye exams part of their midlife health care and provide doctors of optometry with resources to support conversations about eye and vision changes and available care options during menopause.

"Eye and vision health needs to be part of the broader health conversation as women navigate menopause," said Teri K. Geist, O.D., AOA President. iii "A comprehensive eye exam and an open dialogue with your doctor of optometry can help women understand the changes they may be experiencing, identify eye health concerns they may not notice on their own and get the care they need to see and feel their best."

Three simple steps for women :

  • Notice changes: Pay attention to dryness, irritation, blurry near vision, headaches or growing reliance on workarounds.
  • Book a comprehensive eye exam: Don't wait until vision changes interfere with daily life. An annual in-person comprehensive exam is an important part of overall health care and can assess eye and vision health and help identify appropriate solutions.
  • Start the conversation: Tell an eye care professional about menopause-related health changes and how vision is affecting work, reading, driving or other daily activities.

Women can learn more, take a lifestyle quiz and find a local eye doctor nearby by visiting the Vision Made Possible website .

*Disclosure: This is a paid endorsement. Naomi Watts was compensated for this quote.

About Vision at Johnson & Johnson

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at jjvision.com , follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/ . Follow us at @JNJMedTech and on LinkedIn.

About the Study

Ipsos conducted the survey on behalf of Johnson & Johnson from July 31 to August 6, 2026, among 6,000 women ages 35–60 in the United States, United Kingdom, Brazil, South Korea, Japan and China.

Quotas and weighting were used to reflect each market's population. Results for the full sample are accurate within ±1.5 percentage points, and results for each country sample of 1,000 women are accurate within ±3.8 percentage points, 19 times out of 20.

i Johnson & Johnson. Vision Made Possible International Survey. August 2026.
ii Presbyopia. Cleveland Clinic. (2023, July 6). https://my.clevelandclinic.org/health/diseases/8577-presbyopia
iii Teri K. Geist, O.D., serves as President of the American Optometric Association (AOA), which is supporting this Johnson & Johnson effort. Dr. Geist has not been compensated in connection with this press release.

2026PP16998

Media Contacts:
Michelle Parker
MParker5@its.jnj.com

Erin Farley
Efarley1@its.jnj.com

Investor Contact:
Investor-relations@its.jnj.com

News Provided by Business Wire via QuoteMedia

JNJ
The Conversation (0)
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global... Keep Reading...
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition,... Keep Reading...
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at... Keep Reading...

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). As quoted in the press release: The collaboration will explore the potential for Kaleido’s... Keep Reading...

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech. As quoted in the press release: Upon closing, Janssen paid XBiotech $750 million, with $75 million held in escrow for 18 months. Should Janssen pursue... Keep Reading...
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...
Data Safety Monitoring Board  Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...

Interactive Chart

Latest Press Releases

Related News